The investigational drug AZD2171 (cediranib) from Astra-Zeneca may help shrink tumours and prolong survival of patients with a relatively common, aggressive type of brain cancer. In a phase II study of 31 patients with recurrent glioblastoma, researchers observed that daily treatment with cediranib decreased tumour volume by more than half in 56 percent of patients. [...]
Entries Tagged as 'FGF'
Cediranib (AZD2171) in Glioblastoma and brain cancer
July 14th, 2008 · No Comments · FGF, Tie-2, brain cancer, cancer, competitive intelligence, glioblastoma, market intelligence, market trends, oncology
Tags: